Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes (Ellipse™)

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Novo Nordisk A/S
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT01541215
First received: February 23, 2012
Last updated: September 17, 2014
Last verified: September 2014
  Purpose

This trial is conducted globally. The aim of this trial is to assess the efficacy and safety of liraglutide in the paediatric population in order to potentially address the unmet need for treatment of children and adolescents with type 2 diabetes.


Condition Intervention Phase
Diabetes
Diabetes Mellitus, Type 2
Drug: liraglutide
Drug: placebo
Drug: metformin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Liraglutide in Combination With Metformin Versus Metformin Monotherapy on Glycaemic Control in Children and Adolescents With Type 2 Diabetes

Resource links provided by NLM:


Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • Change in HbA1c (glycosylated haemoglobin) [ Time Frame: Week 0, week 26 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Number of subjects having HbA1c below 7.0% [ Time Frame: Week 26 ] [ Designated as safety issue: No ]
  • Number of subjects having HbA1c below 7.0% [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
  • Number of subjects having HbA1c maximum 6.5% [ Time Frame: Week 26 ] [ Designated as safety issue: No ]
  • Number of subjects having HbA1c maximum 6.5% [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
  • Number of subjects having HbA1c below 7.0% without severe or minor hypoglycaemic episodes [ Time Frame: Week 26 ] [ Designated as safety issue: No ]
  • Number of subjects having HbA1c below 7.0% without severe or minor hypoglycaemic episodes [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
  • Change from baseline in fasting plasma glucose (FPG) [ Time Frame: Week 0, week 26 ] [ Designated as safety issue: No ]
  • Change from baseline in fasting plasma glucose (FPG) [ Time Frame: Week 0, week 52 ] [ Designated as safety issue: No ]
  • Change from baseline in 7-point self-measured plasma glucose [ Time Frame: Week 0, week 26 ] [ Designated as safety issue: No ]
  • Change from baseline in 7-point self-measured plasma glucose [ Time Frame: Week 0, week 52 ] [ Designated as safety issue: No ]
  • Change from baseline in body weight [ Time Frame: Week 0, week 26 ] [ Designated as safety issue: No ]
  • Change from baseline in body weight [ Time Frame: Week 0, week 52 ] [ Designated as safety issue: No ]
  • Change from baseline in BMI standard deviation score (SDS) [ Time Frame: Week 0, week 26 ] [ Designated as safety issue: No ]
  • Change from baseline in BMI standard deviation score (SDS) [ Time Frame: Week 0, week 52 ] [ Designated as safety issue: No ]
  • Number of adverse events (AEs) [ Time Frame: Week 26 ] [ Designated as safety issue: No ]
  • Number of adverse events (AEs) [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
  • Number of adverse events (AEs) [ Time Frame: week 104 (1 year follow-up) ] [ Designated as safety issue: No ]
  • Number of adverse events (AEs) [ Time Frame: Week 156 (2 year follow-up) ] [ Designated as safety issue: No ]
  • Number of serious adverse events (SAEs) [ Time Frame: Week 26 ] [ Designated as safety issue: No ]
  • Number of serious adverse events (SAEs) [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
  • Number of serious adverse events (SAEs) [ Time Frame: Week 104 (1 year follow-up) ] [ Designated as safety issue: No ]
  • Number of serious adverse events (SAEs) [ Time Frame: Week 156 (2 year follow-up ) ] [ Designated as safety issue: No ]
  • Growth velocity [ Time Frame: Week 104 (1 year follow-up) ] [ Designated as safety issue: No ]
  • Growth velocity [ Time Frame: Week 156 (2 year follow-up) ] [ Designated as safety issue: No ]
  • Pubertal progression [ Time Frame: Week 104 (1 year follow-up) ] [ Designated as safety issue: No ]
  • Pubertal progression [ Time Frame: Week 156 (2 year follow-up) ] [ Designated as safety issue: No ]

Estimated Enrollment: 172
Study Start Date: November 2012
Estimated Study Completion Date: November 2017
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lira + Met Drug: liraglutide
Administered subcutaneously (s.c., under the skin) once daily.1.8 mg or maximum tolerated dose (MTD: 0.6 mg, 1.2 mg, 1.8 mg) for 26 weeks. Subjects will continue treatment in a 26 week open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.
Drug: metformin
Tablets administered for 26 weeks. Maximum tolerated dose (MTD) between 1000-2000 mg at the discretion of the investigator. Subjects will continue treatment in a 26 week open-labelled extension.
Placebo Comparator: Placebo + Met Drug: placebo
Administered subcutaneously (s.c., under the skin) once daily for 26 weeks. Subjects will discontinue placebo treatment in the open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.
Drug: metformin
Tablets administered for 26 weeks. Maximum tolerated dose (MTD) between 1000-2000 mg at the discretion of the investigator. Subjects will continue treatment in a 26 week open-labelled extension.

  Eligibility

Ages Eligible for Study:   10 Years to 16 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Children and adolescents between the ages of 10-16 years. Subjects cannot turn 17 years and 11 months before the end of treatment (52 weeks)
  • Diagnosis of type 2 diabetes mellitus and treated for at least 90 days with diet and exercise alone, or diet and exercise in combination with metformin monotherapy.
  • HbA1c: 7.0-11% (inclusive) if diet and exercise treated or 6.5-11% (inclusive) if treated with metformin
  • Body mass index (BMI) above 85% percentile of the general age and gender matched population

Exclusion Criteria:

  • Type 1 diabetes
  • Maturity onset diabetes of the young (MODY)
  • Use of any antidiabetic agent other than metformin within 90 days prior to screening. Short term treatment with insulin is allowed
  • Recurrent severe hypoglycaemia or hypoglycaemic unawareness as judged by the investigator
  • History of chronic pancreatitis or idiopathic acute pancreatitis
  • Any clinically significant disorder, except for conditions associated with type 2 diabetes history which in the investigator's opinion could interfere with results of the trial
  • Uncontrolled hypertension, treated or untreated above 99th percentile for age and gender in children
  • Known or suspected abuse of alcohol or drugs/narcotics
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01541215

Contacts
Contact: Novo Nordisk clinicaltrials@novonordisk.com

  Hide Study Locations
Locations
United States, Alabama
Novo Nordisk Clinical Trial Call Center Recruiting
Birmingham, Alabama, United States, 35233
United States, Arizona
Novo Nordisk Clinical Trial Call Center Recruiting
Phoenix, Arizona, United States, 85053
United States, California
Novo Nordisk Clinical Trial Call Center Recruiting
Costa Mesa, California, United States, 92626
Novo Nordisk Clinical Trial Call Center Recruiting
Long Beach, California, United States, 90806-1600
Novo Nordisk Clinical Trial Call Center Recruiting
Los Angeles, California, United States, 90027
Novo Nordisk Clinical Trial Call Center Recruiting
Palo Alto, California, United States, 94305-5208
United States, Connecticut
Novo Nordisk Clinical Trial Call Center Recruiting
New Haven, Connecticut, United States, 06520
United States, Delaware
Novo Nordisk Clinical Trial Call Center Recruiting
Wilmington, Delaware, United States, 19803
United States, Florida
Novo Nordisk Clinical Trial Call Center Recruiting
Melbourne, Florida, United States, 32901
Novo Nordisk Clinical Trial Call Center Recruiting
Miami, Florida, United States, 33155
Novo Nordisk Clinical Trial Call Center Recruiting
Miami, Florida, United States, 33144
Novo Nordisk Clinical Trial Call Center Recruiting
St. Petersburg, Florida, United States, 33701
Novo Nordisk Clinical Trial Call Center Recruiting
Tampa, Florida, United States, 33612
United States, Georgia
Novo Nordisk Clinical Trial Call Center Recruiting
Atlanta, Georgia, United States, 30318
Novo Nordisk Clinical Trial Call Center Recruiting
Atlanta, Georgia, United States, 30322
Novo Nordisk Clinical Trial Call Center Recruiting
Columbus, Georgia, United States, 31904
United States, Indiana
Novo Nordisk Clinical Trial Call Center Recruiting
Bloomington, Indiana, United States, 47401
United States, Iowa
Novo Nordisk Clinical Trial Call Center Recruiting
Iowa City, Iowa, United States, 52242
United States, Kansas
Novo Nordisk Clinical Trial Call Center Recruiting
Topeka, Kansas, United States, 66606
United States, Maryland
Novo Nordisk Clinical Trial Call Center Recruiting
Silver Spring, Maryland, United States, 20910
United States, Massachusetts
Novo Nordisk Clinical Trial Call Center Recruiting
Worcester, Massachusetts, United States, 01655
United States, Michigan
Novo Nordisk Clinical Trial Call Center Recruiting
Detroit, Michigan, United States, 48201
United States, Minnesota
Novo Nordisk Clinical Trial Call Center Recruiting
St. Paul, Minnesota, United States, 55102
United States, Missouri
Novo Nordisk Clinical Trial Call Center Recruiting
Columbia, Missouri, United States, 65201
Novo Nordisk Clinical Trial Call Center Recruiting
Kansas City, Missouri, United States, 64111
United States, Nevada
Novo Nordisk Clinical Trial Call Center Recruiting
Las Vegas, Nevada, United States, 89148
United States, New Jersey
Novo Nordisk Clinical Trial Call Center Recruiting
Hackensack, New Jersey, United States, 07601
Novo Nordisk Clinical Trial Call Center Recruiting
Livingston, New Jersey, United States, 07052
United States, New York
Novo Nordisk Clinical Trial Call Center Recruiting
New York, New York, United States, 10029
Novo Nordisk Clinical Trial Call Center Recruiting
New York, New York, United States, 10016
United States, Ohio
Novo Nordisk Clinical Trial Call Center Recruiting
Cincinnati, Ohio, United States, 45229
Novo Nordisk Clinical Trial Call Center Recruiting
Toledo, Ohio, United States, 43606
United States, Pennsylvania
Novo Nordisk Clinical Trial Call Center Recruiting
Hershey, Pennsylvania, United States, 17033
Novo Nordisk Clinical Trial Call Center Recruiting
Philadelphia, Pennsylvania, United States, 19152
Novo Nordisk Clinical Trial Call Center Recruiting
Pittsburgh, Pennsylvania, United States, 15224
United States, South Carolina
Novo Nordisk Clinical Trial Call Center Recruiting
Greenville, South Carolina, United States, 29615
United States, South Dakota
Novo Nordisk Clinical Trial Call Center Recruiting
Rapid City, South Dakota, United States, 57701
United States, Tennessee
Novo Nordisk Clinical Trial Call Center Recruiting
Memphis, Tennessee, United States, 38119
Novo Nordisk Clinical Trial Call Center Recruiting
Memphis, Tennessee, United States, 38103-2800
United States, Texas
Novo Nordisk Clinical Trial Call Center Recruiting
Dallas, Texas, United States, 75235
Novo Nordisk Clinical Trial Call Center Recruiting
Edinburg, Texas, United States, 78539
Novo Nordisk Clinical Trial Call Center Recruiting
Fort Worth, Texas, United States, 76104
Novo Nordisk Clinical Trial Call Center Recruiting
Houston, Texas, United States, 77025
Novo Nordisk Clinical Trial Call Center Recruiting
Schertz, Texas, United States, 78154
United States, Virginia
Novo Nordisk Clinical Trial Call Center Recruiting
Norfolk, Virginia, United States, 23507
United States, West Virginia
Novo Nordisk Clinical Trial Call Center Recruiting
Charleston, West Virginia, United States, 25302
Australia, Queensland
Recruiting
Ipswich, Queensland, Australia, 4305
Belgium
Recruiting
Brussels, Belgium, 1090
Canada, Manitoba
Recruiting
Winnipeg, Manitoba, Canada, R3E 3P4
Croatia
Recruiting
Zagreb, Croatia, 10 000
Denmark
Recruiting
Herlev, Denmark, 2730
Greece
Recruiting
Athens, Greece, 151 23
Hungary
Recruiting
Budapest, Hungary, 1023
India
Recruiting
Bangalore, Karnataka, India, 560052
Israel
Recruiting
Jerusalem, Israel, 91240
Macedonia, The Former Yugoslav Republic of
Recruiting
Skopje, Macedonia, The Former Yugoslav Republic of, 1000
Mexico
Recruiting
Puebla, Mexico, 72190
Norway
Recruiting
Bergen, Norway, 5021
Romania
Recruiting
Bucharest, Romania, 020614
Russian Federation
Recruiting
Moscow, Russian Federation, 117036
Serbia
Recruiting
Belgrade, Serbia, 11070
Spain
Recruiting
Madrid, Spain, 28046
Sweden
Recruiting
Stockholm, Sweden, 141 86
Turkey
Recruiting
Ankara, Turkey, 06100
United Kingdom
Recruiting
Birmingham, United Kingdom, B4 6NH
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
  More Information

Additional Information:
No publications provided

Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT01541215     History of Changes
Other Study ID Numbers: NN2211-3659, 2011-002605-29, P/288/2010, U1111-1121-8743, CTRI/2013/10/004082
Study First Received: February 23, 2012
Last Updated: September 17, 2014
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration
Belgium: Federal Agency for Medicines and Health Products, FAMHP
Canada: Public Health Agency of Canada
Croatia: Ministry of Health and Social Care
Denmark: Danish Medicines Agency
Greece: Ministry of Health
Hungary: National Institute of Pharmacy
India: Ministry of Health and Family Wellfare
Israel: Israeli Health Ministry Pharmaceutical Administration
Macedonia, The Former Yugoslav Republic of: Ministry of Health
Mexico: National Institute of Public Health, Health Secretariat
Norway: Norwegian Medicines Control Authority
Romania: National Medicines Agency
Russia: Federal Service for Control of Health Care and Social Development
Serbia: Agency for Drugs and Medicinal Devices
Spain: Spanish Agency of Medicines and Health Care Products
Sweden: Medical Products Agency
Turkey: Ministry of Health Drug and Pharmaceutical Department
United Kingdom: Medicines and Healthcare Products Regulatory
United States: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Liraglutide
Metformin
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists

ClinicalTrials.gov processed this record on September 22, 2014